As Congress advances Most Favored Nation (MFN) pricing proposals, lawmakers are overlooking a critical consequence: children with rare diseases could lose access to potentially curative gene therapies. The Institute for Gene Therapies (IGT) is raising concerns that MFN pricing mechanisms would effectively unravel the Medicaid Best Price reforms designed to protect vulnerable patient populations. These reforms have enabled innovative payment models that make high-cost, one-time gene therapies...